NSE: ERIS | BSE: 540596

Mid-range Performer

Download real time

1624.90 39.00 (2.46%)

48.10% Gain from 52W Low

69,644 NSE+BSE Volume

NSE 01 Oct, 2025 3:31 PM (IST)

22,133.3

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

Eris Lifesciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ERIS, BSE:540596 Eris Lifesciences Ltd.

Eris Lifesciences Ltd.

15 Jun 2017

1624.90

2.46%

HDFC sec IPO Note Eris Lifesciences Ltd

IPO Note: Eris Lifesciences Ltd.

HDFC Securities

Eris Lifesciences Ltd Issue Open: June 16 - June 20 2017, Price Band: Rs. 600 - 603

Promoters unpledged 1.58% of shares in last quarter. Total pledge stands at 16.93% of promoter holdings

Eris Lifesciences Ltd.

15 Jun 2017

1624.90

2.46%

IPO Update - Eris Lifesciences Ltd.

IPO Avoid: Eris Lifesciences Ltd.

Choice India

Eris Lifesciences Ltd. (ELL) is a developer, manufacturer and commercializer of branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM....

Number of FII/FPI investors increased from 178 to 193 in Jun 2025 qtr.

Eris Lifesciences Ltd.

15 Jun 2017

1624.90

2.46%

Eris Lifescience Ltd IPO Note Subscribe 14th June

IPO Subscribe: Eris Lifesciences Ltd.

BP Wealth

Eris Lifesciences Ltd is an Ahmedabad, Gujarat based pharmaceutical company, incorporated in 2007 that is engaged in research, development, manufacturing and selling of select therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market. Company's focus has been on developing, manufacturing and marketing products, which are linked to lifestyle related disorders that are chronic in nature and to a target population which primarily consults specialists and superspecialists. Eris products in the chronic category cater primarily to the therapeutic areas including cardiovascular, anti-diabetics and neurology, chronic respiratory and chronic pain (analgesics). In acute category, the product portfolio includes vitamins, gastroenterology, antiinfectives, gynaecology, cute respiratory, acute pain (analgesics), hepatoprotectives, hormones, hematology, dermatology, anti-obesity products and products for injury healing. The product portfolio of the company comprised of 80 Mother Brand Groups as of March 31, 2017. It also owns and...

Eris Lifesciences Ltd. has an average target of 1581.00 from 3 brokers.

Eris Lifesciences Ltd.

14 Jun 2017

1624.90

2.46%

Eris Lifesciences Limited

IPO Subscribe: Eris Lifesciences Ltd.

Angel Broking

Since its inception, the company has been focusing on chronic and specialty acute therapeutic segments. This strategy has played well for the company, as it has gained market share in most of the therapeutic segments of its focus. This has also helped the company to become 32nd largest company by revenue in domestic pharma industry within..

Number of FII/FPI investors increased from 178 to 193 in Jun 2025 qtr.

Eris Lifesciences Ltd.

13 Jun 2017

1624.90

2.46%

Eris Lifesciences - IPO

IPO Subscribe: Eris Lifesciences Ltd.

ICICI Securities Limited

Ahmedabad based Eris Lifesciences (Eris) is a domestic branded formulations focused pharmaceutical company with emphasis on lifestyle related specialised therapeutic areas. The company was promoted by first generation entrepreneur Amit Bakshi in 2007. As on FY17, its product portfolio comprised 80 mother brand groups and is primarily focused on therapies that require the intervention of specialists and super specialists. The acute: chronic ratio was at 66:34 pertaining to FY17 revenues. The company derived ~77% of revenues from metro cities and class-1 towns....

Eris Lifesciences Ltd. is trading above its 200 day SMA of 1507.5

Eris Lifesciences Ltd.

13 Jun 2017

1624.90

2.46%

Eris Lifesciences Ltd.

IPO Subscribe: Eris Lifesciences Ltd.

Ashika Research

The objects of the Offer are to achieve the benefits of listing the Equity Shares on the Stock Exchanges and for the sale of up to 28,875,000 Equity Shares by the Selling Shareholders. Further, Company expects that listing of the Equity Shares will enhance their visibility and brand image and provide liquidity to the shareholders. The Company will not receive any...

Promoters unpledged 1.58% of shares in last quarter. Total pledge stands at 16.93% of promoter holdings

Eris Lifesciences Ltd.

13 Jun 2017

1624.90

2.46%

Eris Lifescience Ltd

IPO Note: Eris Lifesciences Ltd.

SMC online

Incorporated in 2007, Eris Lifescience Ltd is Ahmedabad, Gujrat based pharmaceutical company engaged in research, development, manufacturing and selling of select therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market (IPM). The product portfolio of the company comprised of 80 mother brand groups as of March 31, 2017. The product portfolio is primarily focused on therapeutic areas which require the intervention of specialists and super specialists such as cardiologists, diabetologists, endocrinologists and gastroenterologists. Sales in metro cities and class 1 towns, together accounted for 76.8% of its revenues in Fiscal 2017. Eris Lifescience own...